Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders

Cytokine and Growth Factor Reviews

Volumn 26, Issue 3, 2015, Pages 263-280

  Brisse, Ellen ^a   Wouters, Carine H ^b   Matthys, Patrick ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Animal models; Cytokine storm; Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Therapy

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 6; LEGUMAIN; METHOTREXATE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CYTOKINE;

AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BACTERIAL INFECTION; CELLS BY BODY ANATOMY; CHEDIAK HIGASHI SYNDROME; COMPARATIVE STUDY; CYTOKINE STORM; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE MODEL; EPSTEIN BARR VIRUS; FAMILIAL DISEASE; GENE MUTATION; GRISCELLI SYNDROME; GRISCELLI SYNDROME TYPE 2; HEMOPHAGOCYTIC SYNDROME; HERMANSKY PUDLAK SYNDROME TYPE 2; HERPESVIRIDAE; HERPESVIRUS PAPIO; HUMAN; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOPROLIFERATIVE DISEASE; MURINE CYTOMEGALOVIRUS INFECTION; NONHUMAN; OCULAR ALBINISM; PARASITOSIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TYPE 1 FAMILIAL HEMOPHAGOCYTIC SYNDROME; TYPE 2 FAMILIAL HEMOPHAGOCYTIC SYNDROME; TYPE 3 FAMILIAL HEMOPHAGOCYTIC SYNDROME; TYPE 4 FAMILIAL HEMOPHAGOCYTIC SYNDROME; TYPE 5 FAMILIAL HEMOPHAGOCYTIC SYNDROME; VIRUS INFECTION; X CHROMOSOME LINKED DISORDER; X LINKED LYMPHOPROLIFERATIVE DISEASE; X LINKED LYMPHOPROLIFERATIVE DISEASE TYPE 1; X LINKED LYMPHOPROLIFERATIVE DISEASE TYPE 2; ANIMAL; IMMUNOLOGY; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

ANIMALIA;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

EID: 84929612515     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.001     Document Type: Review

References (150)

1. Scott R., Robb-Smith A. Histiocytic medullary reticulocytosis. Lancet 1939, 2:194-198.
2. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166(2):95-109.
3. Chandrakasan S., Filipovich A.H. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 2013, 163(5):1253-1259.
4. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complications systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604.
5. Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pedriatr Blood Cancer 2007, (48):124-131.
6. Verbsky J.W., Grossman W.J. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 2006, 38(1):20-31.
7. Sieni E., Cetica V., Mastrodicasa E., Pende D., Moretta L., Griffiths G., et al. Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity. Cell Mol Life Sci 2012, 69(1):29-40.
8. Gholam C., Grigoriadou S., Gilmour K.C., Gaspar H.B. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol 2011, 163(3):271-283.
9. Deane S., Selmi C., Teuber S.S., Gershwin M.E. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol 2010, 153(2):109-120.
10. Ramos-Casals M., Brito-Zerón P., López-Guillermo A., Khamashta M.A., Bosch X. Adult haemophagocytic syndrome. Lancet 2013, 6736(13):1-14.
11. Rouphael N.G., Talati N.J., Vaughan C., Cunningham K., Moreira R., Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis 2007, 7:814-822.
12. Ohadi M., Lalloz M.R., Sham P., Zhao J., Dearlove A.M., Shiach C., et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999, 64(1):165-171.
13. Walsh C.M., Matloubian M., Liu C.C., Ueda R., Kurahara C.G., Christensen J.L., et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 1994, 91(23):10854-10858.
14. Kägi D., Ledermann B., Bürki K., Seiler P., Odermatt B., Olsen K.J., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.
15. Kägi D., Hengartnert H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996, 8:472-477.
16. Müllbacher A., Hla R.T., Museteanu C., Simon M.M. Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J Virol 1999, 73(2):1665-1667.
17. Jordan M.B., Hildeman D., Kappler J., Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104(3):735-743.
18. Bolitho P., Voskoboinik I., Trapani J.A., Smyth M.J. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007, 19(3):339-347.
19. Jessen B., Kögl T., Sepulveda F.E., de Saint Basile G., Aichele P., Ehl S. Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol 2013, 4(December):448.
20. Binder D., van den Broek M.F., Kägi D., Bluethmann H., Fehr J., Hengartner H., et al. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med 1998, 187(11):1903-1920.
21. Matloubian M., Suresh M., Glass A., Galvan M., Chow K., Whitmire J.K., et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 1999, 73(3):2527-2536.
22. Pachlopnik Schmid J., Ho C.-H., Chrétien F., Lefebvre J.M., Pivert G., Kosco-Vilbois M., et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009, 1(2):112-124.
23. Sepulveda F.E., Debeurme F., Ménasché G., Kurowska M., CÔte M., Pachlopnik Schmid J., et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 2013, 121(4):595-603.
24. Johnson T.S., Terrell C.E., Millen S.H., Katz J.D., Hildeman D.A., Jordan M.B. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 2014, 192(1):84-91.
25. Lykens J.E., Terrell C.E., Zoller E.E., Risma K., Jordan M.B. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011, 118(3):618-626.
26. Terrell C.E., Jordan M.B. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood 2013, 121(26):5184-5191.
27. Zoller E.E., Lykens J.E., Terrell C.E., Aliberti J., Filipovich A.H., Henson P.M., et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011, 208(6):1203-1214.
28. Orange J.S., Biron C.A. Characterization of early IL-12, IFN-alpha-beta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996, 156:4746-4756.
29. Tay C.H., Welsh R.M. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997, 71(1):267-275.
30. Van Dommelen S.L.H., Sumaria N., Schreiber R.D., Scalzo A.A., Smyth M.J., Degli-Esposti M.A. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 2006, 25(5):835-848.
31. Loh J., Chu D.T., Guin A.K.O., Wayne M., Iv H.W.V., Yokoyama W.M. Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol 2005, 79(1):661-667.
32. Lee S.-H., Kim K.-S., Fodil-Cornu N., Vidal S.M., Biron C.A. Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med 2009, 206(10):2235-2251.
33. Chiossone L., Audonnet S., Chetaille B., Chasson L., Famarier C., Berda-Haddad Y., et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol 2012, 3(August):239.
34. Riera L., Gariglio M., Valente G., Müllbacher A., Museteanu C., Landolfo S., et al. Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection. Eur J Immunol 2000, 30(5):1350-1355.
35. Yang J., Huck S.P., McHugh R.S., Hermans I.F., Ronchese F. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A 2006, 103(1):147-152.
36. Chen M., Felix K., Wang J. Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation. Blood 2012, 119(1):127-136.
37. Feldmann J., Callebaut I., Raposo G., Certain S., Bacq D., Dumont C., et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003, 115(4):461-473.
38. Crozat K., Hoebe K., Ugolini S., Hong N.A., Janssen E., Rutschmann S., et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med 2007, 204(4):853-863.
39. Krebs P., Crozat K., Popkin D., Oldstone M.B., Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 2011, 117(24):6582-6588.
40. + T-cell cytotoxicity and neutrophil degranulation. Eur J Immunol 2013, 43(1):194-208.
41. Kögl T., Müller J., Jessen B., Schmitt-Graeff A., Janka G., Ehl S., et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 2013, 121(4):604-613.
42. Sumegi J., Seemayer T.A., Huang D., Davis J.R., Morra M., Gross T.G., et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma 2002, 43(6):1189-1201.
43. Chan C., Abe M., Hashimoto N., Hao C., Williams I.R., Liu X., et al. Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc Natl Acad Sci U S A 2009, 106(14):468-473.
44. Dotta L., Parolini S., Prandini A., Tabellini G., Antolini M., Kingsmore S.F., et al. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet J Rare Dis 2013, 8(1):168.
45. Usmani G.N., Woda B.A., Newburger P.E. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013, 161(5):609-622.
46. Wilson S.M., Yip R., Swing D.A., O'Sullivan T.N., Zhang Y., Novak E.K., et al. A mutation in Rab27a causes the vesicle transport defects observed in ashen mice. Proc Natl Acad Sci U S A 2000, 97(14):7933-7938.
47. Novak E.K., Gautam R., Reddington M., Collinson L.M., Copeland N.G., Jenkins N.A., et al. The regulation of platelet-dense granules by Rab27a in the ashen mouse, a model of Hermansky-Pudlak and Griscelli syndromes, is granule-specific and dependent on genetic background. Blood 2002, 100(1):128-135.
48. Pachlopnik Schmid J., Ho C.-H., Diana J., Pivert G., Lehuen A., Geissmann F., et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur J Immunol 2008, 38(11):3219-3225.
49. Harris E., Wang N., Wu W., Weatherford A., De A., Cardelli J. Dictyostelium LvsB mutants model the lysosomal defects associated with Chediak-Higashi syndrome. Mol Biol Cell 2002, 13(February):656-669.
50. Runkel F., Büssow H., Seburn K.L., Cox G.A., McVey Ward D., Kaplan J., et al. Grey, a novel mutation in the murine Lyst gene, causes the beige phenotype by skipping of exon 25. Mamm Genome 2006, 17(3):203-210.
51. Rahman M., Haberman A., Tracy C., Ray S., Kramer H. Drosophila mauve mutants reveal a role of LYST homologs late in the maturation of phagosomes and autophagosomes. Traffic 2013, 13(12):1680-1692.
52. Lutzner M.A., Lowrie C.T., Jordan H.W. Giant granules in leukocytes of the beige mouse. J Hered 1964, 58(6):299-300.
53. Holland J.M. Serotonin deficiency and prolonged bleeding in beige mice. Exp Biol Med 1976, 151(1):32-39.
54. Spritz R.A Genetic defects in Chediak-Higashi syndrome and the beige mouse. J Clin Immunol 1998, 18(2):97-105.
55. Jessen B., Maul-Pavicic A., Ufheil H., Vraetz T., Enders A., Lehmberg K., et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 2011, 118(17):4620-4629.
56. Swank R.T., Novak E.K., McGarry M.P., Rusiniak M.E., Feng L. Mouse models of Hermansky-Pudlak syndrome: a review. Pigment Cell Res 1998, 11(2):60-80.
57. Feng L., Seymour A.B., Jiang S., To A., Peden A.A., Novak E.K., et al. The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. Hum Mol Genet 1999, 8(2):323-330.
58. Schmid J.P., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117(5):1-3.
59. Chuang H.-C., Lay J.-D., Hsieh W.-C., Wang H.-C., Chang Y., Chuang S.-E., et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005, 106(9):3090-3096.
60. Wu C., Nguyen K.B., Pien G.C., Wang N., Gullo C., Howie D., et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2001, 2(5):410-414.
61. Czar M.J., Kersh E.N., Mijares L.A., Lanier G., Lewis J., Yap G., et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A 2001, 98(13):7449-7454.
62. Yin L., Al-Alem U., Liang J., Tong W.-M., Li C., Badiali M., et al. Mice deficient in the X-linked lymphoproliferative disease gene sap exhibit increased susceptibility to murine gammaherpesvirus-68 and hypo-gammaglobulinemia. J Med Virol 2003, 71(3):446-455.
63. Pasquier B., Yin L., Fondanèche M.-C., Relouzat F., Bloch-Queyrat C., Lambert N., et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005, 201(5):695-701.
64. Rumble J.M., Oetjen K.A., Stein P.L., Schwartzberg P.L., Moore B.B., Duckett C.S. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell Immunol 2009, 259(1):82-89.
65. Rivat C., Booth C., Alonso-Ferrero M., Blundell M., Sebire N.J., Thrasher A.J., et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood 2013, 121(7):1073-1076.
66. Crotty S., McCausland M.M., Aubert R.D., Wherry E.J., Ahmed R. Hypogammaglobulinemia and exacerbated CD8 T-cell-mediated immunopathology in SAP-deficient mice with chronic LCMV infection mimics human XLP disease. Blood 2006, 108(9):3085-3093.
67. Chen G., Tai A.K., Lin M., Chang F., Huber B.T., Terhorst C. Signaling lymphocyte activation molecule-associated protein is a negative regulator of the CD8 T cell response in mice. J Immunol 2005, 175:2212-2218.
68. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B., et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010, 116(7):1079-1082.
69. Harlin H., Reffey S.B., Duckett C.S., Lindsten T. Characterization of XIAP-deficient mice. Mol Cell Biol 2001, 21(10):3604-3608.
70. Manoury B., Mazzeo D., Fugger L., Viner N., Ponsford M., Streeter H., et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol 2002, 3(2):169-174.
71. Ishii E., Yoshida N., Kimura N., Fujimoto J., Mizutani S., Sako M., et al. Clonal dissemination of T-lymphocytes in scid mice from familial hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 1999, 32:201-208.
72. Yoshida N., Ishii E., Oshima K., Yanai F., Ogawa A., Kataoka S., et al. Engraftment and dissemination of T lymphocytes from primary haemophagocytic lymphohistiocytosis in scid mice. Br J Haematol 2003, 121(2):349-358.
73. Terrell C.E., Jordan M.B. Mixed hematopoietic or T cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood 2013, 122(15):2618-2621.
74. Grom A., Villanueva J., Lee S., Goldmuntz E., Passo M., Filipovich A.H. Natural killer cell dysfunction in patients with systemic-onset rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 292-296.
75. Ramanan A.V., Schneider R. Macrophage activation syndrome-what's in a name!. J Rheumatol 2003, 30(12):2513-2516.
76. Kogawa K., Lee S.M., Villanueva J., Marmer D., Sumegi J., Filipovich A.H. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002, 99(1):61-66.
77. Zhang M., Behrens E.M., Atkinson T.P., Shakoory B., Grom A.A., Cron R.Q. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep 2014, 16(9):439.
78. Tiab M., Mechinaud F., Harousseau J.L. Haemophagocytic syndrome associated with infections. Baillieres Best Pract Res Clin Haematol 2000, 13(2):163-178.
79. Sato K., Misawa N., Nie C., Satou Y., Iwakiri D., Matsuoka M., et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011, 117(21):5663-5673.
80. Yajima M., Imadome K.-I., Nakagawa A., Watanabe S., Terashima K., Nakamura H., et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008, 198(5):673-682.
81. Imadome K., Yajima M., Arai A., Nakazawa A., Kawano F., Ichikawa S., et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 2011, 7(10):e1002326.
82. Tsuge I., Morishima T., Kimura H., Kuzushima K., Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol 2001, 64(2):141-148.
83. Henter J.-I., Chow C.-B., Leung C.-W., Lau Y.-L. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 2006, 367(9513):870-873.
84. Yoshioka M., Kikuta H., Ishiguro N., Endo R., Kobayashi K. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome. J Med Virol 2003, 70(3):410-419.
85. Ito Y., Kawamura Y., Iwata S., Kawada J., Yoshikawa T., Kimura H. Demonstration of Type II latency in T lymphocytes of Epstein-Barr. Pediatr Blood Cancer 2013, (60):326-328.
86. Kasahara Y., Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 2002, 44:283-294.
87. Hayashi K., Ohara N., Teramoto N., Onoda S., Chen H.-L., Oka T., et al. An animal model for human EBV-associated hemophagocytic syndrome. Herpesvirus papio frequently induces fatal lymphoproliferative disorders with hemophagocytic syndrome in rabbits. Am J Pathol 2001, 158(4):2-5.
88. Hayashi K., Jin Z., Onoda S., Joko H., Teramoto N., Ohara N., et al. Rabbit model for human EBV-associated hemophagocytic syndrome (HPS), Sequential autopsy analysis and characterization of IL-2 dependent cell lines established from Herpesvirus papio-induced fatal rabbit lymphoproliferative disease with HPS. Am J Pathol 2003, 162(5):1721-1736.
89. Hsieh W.-C., Chang Y., Hsu M-C., Lan B.-S., Hsiao G.-C., Chuang H.-C., et al. Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome. Am J Pathol 2007, 170(5):1629-1639.
90. Hsieh W.-C., Lan B.-S., Chen Y.-L., Chang Y., Chuang H.-C., Su I.-J. Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model. Antivir Ther 2010, 15(1):71-81.
91. Hayashi K., Joko H., Koirala T.R., Onada S., Jin Z.-S., Munemasa M., et al. Therapeutic trials for a rabbit model of EBV-associated Hemophagocytic Syndrome (HPS): effects of vidarabine or CHOP, and development of Herpesvirus papio (HVP)-negative lymphomas surrounded by HVP-infected lymphoproliferative disease. Histol Histopathol 2003, 18(4):1155-1168.
92. Chuang H.-C., Lay J.-D., Hsieh W.-C., Su I.-J. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 2007, 98(9):1281-1287.
93. Udden M., Banez E., Sears D. Bone marrow histiocytic hyperplasia and hemophagocytosis with pancytopenia in typhoid fever. Am J Med Sci 1986, 291(6).
94. Khalaf D., Toema B., Al-sadadi S., Al-jehani F., Sammak M. Salmonella Typhi associated hemophagocytic lymphohistiocytosis in a previously healthy 23 years old woman. Webmed Cent 2011, 2(WMC001751).
95. Nath U., Sinha N. Hemophagocytic lymphohistiocytosis secondary to Salmonella paratyphi a infection presenting with severe pancytopenia and multiorgan dysfunction. J Bone Marrow Res 2013, 1(2).
96. Brown D.E., McCoy M.W., Pilonieta M.C., Nix R.N., Detweiler C.S. Chronic murine typhoid fever is a natural model of secondary hemophagocytic lymphohistiocytosis. PLoS ONE 2010, 5(2):e9441.
97. McCoy M.W., Moreland S.M., Detweiler C.S. Hemophagocytic macrophages in murine typhoid fever have an anti-inflammatory phenotype. Infect Immun 2012, 80(10):3642-3649.
98. Ansuini V., Rigante D., Esposito S. Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis 2013, 13(1):15.
99. Naessens J. Bovine trypanotolerance: a natural ability to prevent severe anaemia and haemophagocytic syndrome?. Int J Parasitol 2006, 36(5):521-528.
100. Valli V.E.O., Mills J.N., Lumsden J.H., Rattray J.B., Forsberg C.M. The quantitation of Trypanosoma congolense in calves. II. Biochemical changes. Tropenmed Parasitol 1980, 31(3):288-298.
101. Lutje V., Mertens B., Boulangé A., Williams D., Authié E. Trypanosoma congolense: proliferative responses and interleukin production in lymph node cells of infected cattle. Exp Parasitol 1995, 81:154-164.
102. Logan-Henfrey L., Anosa V.O., Wells C.W. The role of the bone marrow in bovine trypanotolerance I. Changes in blood and bone marrow in Trypanosoma congolense-infected cattle. Comperative Haematol Int 1999, 9:198-207.
103. O'Gorman G.M., Park S.D.E., Hill E.W., Meade K.G., Mitchell L.C., Agabe M., et al. Cytokine mRNA profiling of peripheral blood mononuclear cells from trypanotolerant and trypanosusceptible cattle infected with Trypanosoma congolense. Physiol Genomics 2006, 28:53-61.
104. Magez S., Radwanska M., Beschin A., Sekikawa K., De Baetselier P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 1999, 67(6):3128-3132.
105. Namangala B., Noël W., De Baetselier P., Brys L., Beschin A. Relative contribution of interferon-gamma and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis 2001, 183(12):1794-1800.
106. Kitani H., Yagi Y., Naessens J., Sekikawa K., Iraqi F. The secretion of acute phase proteins and inflammatory cytokines during Trypanosoma congolense infection is not affected by the absence of the TNF-alpha gene. Acta Trop 2004, 92(1):35-42.
107. Magez S., Truyens C., Merimi M., Radwanska M., Stijlemans B., Brouckaert P., et al. P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis 2004, 189(3):527-539.
108. Stijlemans B., Vankrunkelsven A., Brys L., Magez S., De Baetselier P. Role of iron homeostasis in trypanosomiasis-associated anemia. Immunobiology 2008, 213(9-10):823-835.
109. Guegan F., Plazolles N., Baltz T., Coustou V. Erythrophagocytosis of desialylated red blood cells is responsible for anaemia during Trypanosoma vivax infection. Cell Microbiol 2013, 15(8):1285-1303.
110. Freeman H.R., Ramanan A.V. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child 2011, 96(7):688-693.
111. Maakaroun N.R., Moanna A., Jacob J.T., Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol 2010, (February):93-105.
112. Behrens E.M., Canna S.W., Slade K., Rao S., Kreiger P.A., Paessler M., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121(6):2264-2277.
113. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(2):187-192.
114. Canna S.W., Wrobel J., Chu N., Kreiger P.A., Paessler M., Behrens E.M. Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 2013, 65(7):1764-1775.
115. Ohyagi H., Onai N., Sato T., Yotsumoto S., Liu J., Akiba H., et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 2013, 39(3):584-598.
116. Canna S.W., Costa-Reis P., Bernal W.E., Chu N., Sullivan K.E., Paessler M.E., et al. Alternative activation of laser-captured murine hemophagocytes. Arthritis Rheumatol 2014, 66(6):1666-1671.
117. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34(5):1133-1138.
118. De Benedetti F., Alonzi T., Moretta A., Lazzaro D., Costa P., Poli V., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997, 99(4):643-650.
119. De Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006, 54(11):3551-3563.
120. Strippoli R., Carvello F., Scianaro R., De Pasqaule L., Vivarelli M., Petrini S., et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 2012, 64(5):1680-1688.
121. Strippoli R., Caiello I., De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol 2013, 40(6):761-767.
122. Avau A., Mitera T., Put S., Put K., Brisse E., Filtjens J., et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-γ. Arthritis Rheumatol 2014, 66(5):1340-1351.
123. Jordan M.B., Allen C.E., Weitzman S., Filipovich A.H., McClain K.L., How I. treat hemophagocytic lymphohistiocytosis. Blood 2011, 118(15):4041-4052.
124. Rothman J.A., Das R., Teachey D.T., Paessler M.E., Nichols K.E. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatr Blood Cancer 2011, (June):1239-1243.
125. Henter J.I., Elinder G., Soder O., Hansson M., Andersson B., U Andersson Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991, 78(11):2918-2922.
126. Créput C., Galicier L., Buyse S., Azoulay E. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. Intensive Care Med 2008, 34(7):1177-1187.
127. Lachmann H.J., Quartier P., So A., Hawkins P.N. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum 2011, 63(2):314-324.
128. Moore K.W., Malefyt R.D.W., Robert L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001, 19:683-765.
129. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013, 4(October):289.
130. De Kerguenec C., Hillaire S., Molinié V., Gardin C., Degott C., Erlinger S., et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 2001, 96(3):852-857.
131. Avau A., Put K., Wouters C.H., Matthys P. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis. Cytokine Growth Factor Rev 2014, 10.1016/j.cytogfr.2014.05.005.
132. Schulert G.S., Grom A.A. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol 2014, 28(2):277-292.
133. Akashi K., Hayashi S., Gondo H., Mizuno S.-I., Harada M., Tamura K., et al. Involvement of interferon-γ and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 1994, 87(2):243-250.
134. Osugi Y., Hara J., Tagawa S., Takai K., Hosoi G., Matsuda Y., et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997, 89(11):4100-4103.
135. Billiau A.D., Roskams T., Van Damme-Lombaerts R., Matthys P., Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated. IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005, 105(4):1648-1651.
136. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106(10):3483-3489.
137. Xu X.-J., Tang Y.-M., Song H., Yang S.L., Xu W.Q., Zhao N., et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 2012, 160(6). 984-90.e1.
138. Imashuku S., Hibi S., Fujiwara F., Ikushima S., Todo S. Haemophagocytic lymphohistiocytosis, interferon-gamma-naemia and Epstein-Barr virus involvement. Br J Haematol 1994, 88(3):656-658.
139. Maruyama J., Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010, 37(5):967-973.
140. Sumegi J., Barnes M.G., Nestheide S.V., Molleran-Lee S., Villanueva J., Zhang K., et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 2011, 117(15):e151-e160.
141. Nold-Petry C.A., Lehrnbecher T., Jarisch A., Schwabe D., Pfeilschifter J.M., Muhl H., et al. Failure of interferon gamma to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis. PLoS ONE 2010, 5(1):e8663.
142. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010, 49(9):1645-1653.
143. Henzan T., Nagafuji K., Tsukamoto H., Miyamoto T., Gondo H., Imashuku S., et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 2006, 81(1):59-61.
144. Mischler M., Fleming G.M., Shanley T.P., Madden L., Levine J., Castle V., et al. Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics 2007, 119(5). e1212-8.
145. Strout M.P., Seropian S., Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010, 7(7):415-420.
146. Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment. Joint Bone Spine 2012, 79(4):356-361.
147. Tak P.P., Bacchi M., Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006, 31(2):109-116.
148. Kobayashi M., Takahashi Y., Yamashita H., Kaneko H., Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011, 21(1):92-96.
149. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2385-2395.
150. Asadullah K., Sterry W., Volk H. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55(2):241-269.